In terms of cell cycle regulation, EFE blocks the cell cycle through the ROS/JNK pathway in lung cancer,[56] and in cervical cancer, it has been newly discovered that it effectively inhibits tumor cell proliferation by down-regulating the expression of cyclin D1, a key target gene of the NF-κB signaling pathway, through EETs.[44,45] This cycle blocking effect forms a synergy with its proapoptotic effect and jointly inhibits tumor growth. Here, NFKB1 is linked to lung carcinoma.